Bharat Biotech setting up Covaxin-manufacturing unit in K'taka: Deputy CM

Karnataka will soon have a Covaxin-manufacturing plant of Bharat Biotech in Kolar district near, says Deputy Chief Minister of the State Dr C N Ashwath Narayan

Bharat Biotech setting up Coxain-manufacturing unit in K'taka: Deputy CM
Press Trust of India Bengaluru
2 min read Last Updated : May 14 2021 | 8:29 PM IST

: Karnataka will soon have a

Covaxin-manufacturing plant of Bharat Biotech in Kolar district near here, Deputy Chief Minister of the State Dr C N Ashwath Narayan said on Friday.

The construction work has already begun and the government has invited investors to make the vaccine in the State, he said.

"Covaxin vaccine-manufacturing plant of Bharat Biotech will be established at the earliest in Malur Industrial Area of neighbouring Kolar district," Narayan, who is the IT-BT Minister and heads the State Covid task force, said in a statement.

"The government has approved the project and the company is processing administrative requisites. Civil construction works have already been started and this will be completed soon to facilitate the functioning of the manufacturing operations as early as possible, he said.

According to him, Malur, which is close to the State capital, has good transport facilities.

He said the State would welcome and give full cooperation to any company engaged in the vaccine- manufacturing.

In order to combat the second wave and as a preparation to face the possible third wave, every Assembly constituency in the State needs to have a 100-bed hospital with oxygenated and ICU beds, he said.

So far, 1.10 crore people in the State have been inoculated but vaccination for people in the age group of 18 -44 has been put off due to the shortage of vaccine.

The government has ordered three crore vaccines and has paid money to the manufacturers but till now so far only seven lakh vaccines have been received.

The State has reported 41,779 fresh cases and 373 fatalities despite stringent restrictions on the movement of people from April 27 till May 24.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusBharat BiotechCoronavirus VaccineKarnataka

First Published: May 14 2021 | 8:14 PM IST

Next Story